Tvardi Therapeutics (NASDAQ:TVRD) Upgraded to Sell at Wall Street Zen

Wall Street Zen upgraded shares of Tvardi Therapeutics (NASDAQ:TVRD) from a strong sell rating to a sell rating in a report issued on Saturday morning.

Other equities research analysts also recently issued reports about the company. Raymond James Financial raised Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 target price on the stock in a research report on Wednesday, July 8th. UBS Group raised Tvardi Therapeutics to an “outperform” rating and set a $10.00 price objective on the stock in a report on Wednesday, July 8th. Weiss Ratings restated a “sell (e+)” rating on shares of Tvardi Therapeutics in a research report on Wednesday, July 8th. HC Wainwright initiated coverage on Tvardi Therapeutics in a research note on Monday, June 8th. They issued a “buy” rating and a $9.00 target price for the company. Finally, Piper Sandler raised Tvardi Therapeutics from a “neutral” rating to an “overweight” rating and set a $13.00 target price for the company in a research report on Wednesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Tvardi Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $18.00.

Tvardi Therapeutics Trading Up 1.6%

Shares of Tvardi Therapeutics stock opened at $1.86 on Friday. The company’s fifty day simple moving average is $2.40 and its 200-day simple moving average is $3.11. The company has a market cap of $24.81 million, a price-to-earnings ratio of -0.67 and a beta of 0.39. Tvardi Therapeutics has a 1 year low of $1.50 and a 1 year high of $43.65.

Tvardi Therapeutics (NASDAQ:TVRD) last announced its earnings results on Friday, August 14th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). As a group, research analysts forecast that Tvardi Therapeutics will post -2.35 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Tvardi Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC acquired a new stake in Tvardi Therapeutics in the 2nd quarter valued at $2,617,000. JPMorgan Chase & Co. acquired a new position in Tvardi Therapeutics during the second quarter worth $39,000. New York State Common Retirement Fund acquired a new position in Tvardi Therapeutics during the second quarter worth $92,000. Marshall Wace LLP bought a new position in shares of Tvardi Therapeutics during the second quarter valued at $583,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Tvardi Therapeutics during the second quarter valued at $43,000. Institutional investors own 44.66% of the company’s stock.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.